This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Johnson & Johnson says CareFirst lacks standing to challenge enforceability of Stelara patent in US antitrust case

( July 1, 2024, 22:31 GMT | Official Statement) -- MLex Summary: CareFirst, as an indirect purchaser of Stelara, cannot collaterally attack the enforceability of a Johnson & Johnson patent covering a method for using ustekinumab, J&J told a US federal judge. “J&J’s patent has never been enforced against plaintiffs, and the parties against whom it was enforced chose to settle those disputes rather than pursue the type of challenge plaintiffs attempt in this case. Those patent settlements are demonstrably procompetitive, in that they allow competitors to enter the market years before the earliest expiration date of the patents owned by J&J,” the company said in a filing. See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections